213 related articles for article (PubMed ID: 20015094)
1. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.
Ly D; Tohn R; Rubin B; Blumenfeld H; Besra GS; Veerapen N; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2010 May; 160(2):185-98. PubMed ID: 20015094
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.
Tohn R; Blumenfeld H; Haeryfar SM; Veerapen N; Besra GS; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2011 Apr; 164(1):26-41. PubMed ID: 21361909
[TBL] [Abstract][Full Text] [Related]
3. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice.
Blumenfeld HJ; Tohn R; Haeryfar SM; Liu Y; Savage PB; Delovitch TL
Clin Exp Immunol; 2011 Oct; 166(1):121-33. PubMed ID: 21910729
[TBL] [Abstract][Full Text] [Related]
4. Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis.
Yoshiga Y; Goto D; Segawa S; Horikoshi M; Hayashi T; Matsumoto I; Ito S; Taniguchi M; Sumida T
Clin Exp Immunol; 2011 May; 164(2):236-47. PubMed ID: 21391989
[TBL] [Abstract][Full Text] [Related]
5. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vitro evaluation of alpha-GalCer epimers.
Trappeniers M; Goormans S; Van Beneden K; Decruy T; Linclau B; Al-Shamkhani A; Elliott T; Ottensmeier C; Werner JM; Elewaut D; Van Calenbergh S
ChemMedChem; 2008 Jul; 3(7):1061-70. PubMed ID: 18418814
[TBL] [Abstract][Full Text] [Related]
7. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator.
Forestier C; Takaki T; Molano A; Im JS; Baine I; Jerud ES; Illarionov P; Ndonye R; Howell AR; Santamaria P; Besra GS; Dilorenzo TP; Porcelli SA
J Immunol; 2007 Feb; 178(3):1415-25. PubMed ID: 17237389
[TBL] [Abstract][Full Text] [Related]
8. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
9. α-Galactosylceramide treatment before allergen sensitization promotes iNKT cell-mediated induction of Treg cells, preventing Th2 cell responses in murine asthma.
Chen Q; Guo X; Deng N; Liu L; Chen S; Wang A; Li R; Huang Y; Ding X; Yu H; Hu S; Nie H
J Biol Chem; 2019 Apr; 294(14):5438-5455. PubMed ID: 30745361
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of hydroxylated analogues of KRN7000 (α-galactosylceramide).
Shiozaki M; Tashiro T; Koshino H; Shigeura T; Watarai H; Taniguchi M; Mori K
Carbohydr Res; 2013 Apr; 370():46-66. PubMed ID: 23454137
[TBL] [Abstract][Full Text] [Related]
11. Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration.
Kuns RD; Morris ES; Macdonald KP; Markey KA; Morris HM; Raffelt NC; Banovic T; Don AL; Rowe V; Burman AC; Clouston AD; Farah C; Besra GS; Illarionov PA; Smyth MJ; Porcelli SA; Hill GR
Blood; 2009 Jun; 113(23):5999-6010. PubMed ID: 19369232
[TBL] [Abstract][Full Text] [Related]
12. Modulation of NKT cells and Th1/Th2 imbalance after alpha-GalCer treatment in progressive load-trained rats.
Ru W; Peijie C
Int J Biol Sci; 2009 May; 5(4):338-43. PubMed ID: 19461936
[TBL] [Abstract][Full Text] [Related]
13. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activities of amino acids functionalized α-GalCer analogues.
Ma W; Bi J; Zhao C; Zhang Z; Liu T; Zhang G
Bioorg Med Chem; 2020 Jan; 28(1):115141. PubMed ID: 31786009
[TBL] [Abstract][Full Text] [Related]
15. Distinct APCs explain the cytokine bias of α-galactosylceramide variants in vivo.
Bai L; Constantinides MG; Thomas SY; Reboulet R; Meng F; Koentgen F; Teyton L; Savage PB; Bendelac A
J Immunol; 2012 Apr; 188(7):3053-61. PubMed ID: 22393151
[TBL] [Abstract][Full Text] [Related]
16. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
17. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells.
Ly D; Mi QS; Hussain S; Delovitch TL
J Immunol; 2006 Sep; 177(6):3695-704. PubMed ID: 16951329
[TBL] [Abstract][Full Text] [Related]
18. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
Front Immunol; 2019; 10():352. PubMed ID: 30881361
[TBL] [Abstract][Full Text] [Related]
19. 3-fluoro- and 3,3-difluoro-3,4-dideoxy-KRN7000 analogues as new potent immunostimulator agents: total synthesis and biological evaluation in human invariant natural killer T cells and mice.
Hunault J; Diswall M; Frison JC; Blot V; Rocher J; Marionneau-Lambot S; Oullier T; Douillard JY; Guillarme S; Saluzzo C; Dujardin G; Jacquemin D; Graton J; Le Questel JY; Evain M; Lebreton J; Dubreuil D; Le Pendu J; Pipelier M
J Med Chem; 2012 Feb; 55(3):1227-41. PubMed ID: 22243602
[TBL] [Abstract][Full Text] [Related]
20. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
